The U.S. Department of Health and Human Services (HHS) is buying $290 million worth of drugs as part of its “long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies.”
HHS is purchasing a supply of the drug Nplate from Amgen USA, a biotechnology headquartered in Thousand Oaks, California.
